Safety under the regulatory spotlight — 120 documents in 90 days

58 documents in the last 30 days alone

This concentration of safety-related regulatory documents may indicate a tightening cycle, or at least a period of heightened scrutiny, because a large share of recent activity appears to be clustering around risk management, signal evaluation, and post-market expectations. Sponsors should consider watching for more explicit expectations on pharmacovigilance, benefit-risk justification, and how emerging safety findings are communicated across labels, studies, and lifecycle submissions, as this could suggest regulators are sharpening their focus rather than easing it.